Facebook
Twitter
LinkedIn
ForwardOptimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas
The goal of this program is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with relapsed/refractory B-cell lymphomas.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who care for patients with relapsed/refractory B-cell lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the standard of care and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
- Discuss the mechanism of action and evidence from clinical trials supporting the use of novel small molecule inhibitors in the management of patients with relapsed/refractory B-cell lymphomas.
- Identify the special considerations associated with the use of currently approved small molecule inhibitors to develop an individualized treatment plan for patients with relapsed/refractory B-cell lymphomas.
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Andrew D. Zelenetz, MD, PhD
Adaptive Biotechnologies Corporation: Consulting Fee
Amgen Inc.: Consulting Fee
BeiGene: Other financial benefit
Celgene Corporatio: Consulting Fee
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
MEI Pharma Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.90 contact hour.
Pharmacists
| National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-0000-18-122-H01-P
Available Credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 0.90 ANCC contact hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- Adobe Reader or other PDF reader software for certificate viewing/printing